Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 3/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | NPR1 | P16066 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10068133 | 0.91 | LMNA (0.38) | NRP1LOXL2TRIM24SCN9ABRD4 | |
| SCHEMBL4572327 | 0.87 | NRP1 (0.55) | NRP1NPR1 | |
| SCHEMBL10067798 | 0.86 | BRD4 (0.38) | NRP1NPR1BRD4 | |
| SCHEMBL4572278 | 0.86 | LARS1 (0.47) | NRP1PTGES2LARS1NPR1 | |
| SCHEMBL4572328 | 0.85 | PTGES2 (0.50) | NRP1PTGES2LARS1NPR1 | |
| SCHEMBL4572342 | 0.82 | NRP1 (0.49) | NRP1 | |
| SCHEMBL13554544 | 0.81 | NRP1 (0.42) | NRP1NPR1KDRBRD4 | |
| SCHEMBL4572266 | 0.81 | BRD4 (0.43) | NRP1BRD4 | |
| SCHEMBL4572325 | 0.81 | PTGES2 (0.51) | NRP1PTGES2 | |
| SCHEMBL4569886 | 0.79 | TRIM24 (0.49) | NRP1LOXL2TRIM24PTGES2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885LOXL2 4623/4885TRIM24 3199/4885 |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | NRP1 145/4885LOXL2 4623/4885TRIM24 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.